Corporate Board Profile
Tech Score: 67/100
2 mention(s) identify DR. PEARL S. HUANG, PH.D. as having software/technology expertise.
| Company | Filing Date | Evidence | Reason |
|---|---|---|---|
| WATERS CORP /DE/ | 2022-04-14 | President and CEO of Cygnal Therapeutics (Jan. 2019 – Present) Venture Partner at Flagship Pioneering (Jan. 2019-Present) Senior Vice President and Global Head of Therapeutic Modalities. F. Hoffman La-Roche, Ltd. (Dec. 2014 – Dec. 2018) Vice President and Global Head of Discovery Academic Partnerships (DPAc) Alternative Discovery and Development, GlaxoSmithKline plc (2012-2014) Founder and CSO, Beigene LTD (2010-2012) Vice President, Oncology Integrator, Discovery and Early Development, Merck and Co. (2006-2010) Held roles of increasing responsibility at Merck & Co. Inc., GlaxoSmithKline plc, and Bristol Myers Squibb Co. | She has deep scientific knowledge and operational experience in pharmaceutical sector, including roles that suggest technical expertise potentially related to software and technology. |
| WATERS CORP /DE/ | 2023-04-13 | Dr. Huang earned a BS in biology from MIT and a Ph.D. in molecular biology from Princeton University. | Dr. Huang has a PhD in molecular biology and a BS in biology from MIT, with extensive scientific and operational experience in pharmaceuticals, indicating a strong technical background potentially including programming skills. |
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-01 | Dr. Huang brings both operational and deep scientific knowledge along with extensive international and operational experience in the pharmaceutical sector both in senior leadership and operational roles. |
| 2022-04-14 | President and CEO of Cygnal Therapeutics (Jan. 2019 – Present) Venture Partner at Flagship Pioneering (Jan. 2019-Present) Senior Vice President and Global Head of Therapeutic Modalities. F. Hoffman La-Roche, Ltd. (Dec. 2014 – Dec. 2018) Vice President and Global Head of Discovery Academic Partnerships (DPAc) Alternative Discovery and Development, GlaxoSmithKline plc (2012-2014) Founder and CSO, Beigene LTD (2010-2012) Vice President, Oncology Integrator, Discovery and Early Development, Merck and Co. (2006-2010) Held roles of increasing responsibility at Merck & Co. Inc., GlaxoSmithKline plc, and Bristol Myers Squibb Co. |
| 2023-04-13 | Dr. Huang earned a BS in biology from MIT and a Ph.D. in molecular biology from Princeton University. |
Data sourced from SEC filings. Last updated: 2025-10-12